Figure 3From: Prognostic value of monitoring tumour markers CA 15-3 and CEA during fulvestrant treatmentObserved changes in CA 15-3 levels in patients 3 months prior to secondary progression after experiencing clinical benefit with fulvestrant treatment (n = 28).Back to article page